Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 592

1.

AML1-ETO downregulates the granulocytic differentiation factor C/EBPalpha in t(8;21) myeloid leukemia.

Pabst T, Mueller BU, Harakawa N, Schoch C, Haferlach T, Behre G, Hiddemann W, Zhang DE, Tenen DG.

Nat Med. 2001 Apr;7(4):444-51.

PMID:
11283671
2.

The myeloid master regulator transcription factor PU.1 is inactivated by AML1-ETO in t(8;21) myeloid leukemia.

Vangala RK, Heiss-Neumann MS, Rangatia JS, Singh SM, Schoch C, Tenen DG, Hiddemann W, Behre G.

Blood. 2003 Jan 1;101(1):270-7. Epub 2002 Aug 29.

3.

Dominant-negative mutations of CEBPA, encoding CCAAT/enhancer binding protein-alpha (C/EBPalpha), in acute myeloid leukemia.

Pabst T, Mueller BU, Zhang P, Radomska HS, Narravula S, Schnittger S, Behre G, Hiddemann W, Tenen DG.

Nat Genet. 2001 Mar;27(3):263-70.

PMID:
11242107
4.

Persistence of multipotent progenitors expressing AML1/ETO transcripts in long-term remission patients with t(8;21) acute myelogenous leukemia.

Miyamoto T, Nagafuji K, Akashi K, Harada M, Kyo T, Akashi T, Takenaka K, Mizuno S, Gondo H, Okamura T, Dohy H, Niho Y.

Blood. 1996 Jun 1;87(11):4789-96.

5.

The fusion protein AML1-ETO in acute myeloid leukemia with translocation t(8;21) induces c-jun protein expression via the proximal AP-1 site of the c-jun promoter in an indirect, JNK-dependent manner.

Elsässer A, Franzen M, Kohlmann A, Weisser M, Schnittger S, Schoch C, Reddy VA, Burel S, Zhang DE, Ueffing M, Tenen DG, Hiddemann W, Behre G.

Oncogene. 2003 Aug 28;22(36):5646-57.

PMID:
12944913
6.

The AML1 gene: a transcription factor involved in the pathogenesis of myeloid and lymphoid leukemias.

Lo Coco F, Pisegna S, Diverio D.

Haematologica. 1997 May-Jun;82(3):364-70. Review.

7.

AML1/ETO-induced survivin expression inhibits transcriptional regulation of myeloid differentiation.

Balkhi MY, Christopeit M, Chen Y, Geletu M, Behre G.

Exp Hematol. 2008 Nov;36(11):1449-60. doi: 10.1016/j.exphem.2008.05.008. Epub 2008 Aug 8.

PMID:
18687517
8.

Characterization of the ETO and AML1-ETO proteins involved in 8;21 translocation in acute myelogenous leukemia.

Le XF, Claxton D, Kornblau S, Fan YH, Mu ZM, Chang KS.

Eur J Haematol. 1998 Apr;60(4):217-25.

PMID:
9579874
9.
10.

Repression of vascular endothelial growth factor expression by the runt-related transcription factor 1 in acute myeloid leukemia.

Ter Elst A, Ma B, Scherpen FJ, de Jonge HJ, Douwes J, Wierenga AT, Schuringa JJ, Kamps WA, de Bont ES.

Cancer Res. 2011 Apr 1;71(7):2761-71. doi: 10.1158/0008-5472.CAN-10-0402. Epub 2011 Mar 29.

11.
12.
13.
14.

AML1 and the AML1-ETO fusion protein in the pathogenesis of t(8;21) AML.

Licht JD.

Oncogene. 2001 Sep 10;20(40):5660-79. Review. No abstract available.

15.

ELA2 is regulated by hematopoietic transcription factors, but not repressed by AML1-ETO.

Lausen J, Liu S, Fliegauf M, Lübbert M, Werner MH.

Oncogene. 2006 Mar 2;25(9):1349-57.

PMID:
16247445
16.

AML1/MTG8 oncogene suppression by small interfering RNAs supports myeloid differentiation of t(8;21)-positive leukemic cells.

Heidenreich O, Krauter J, Riehle H, Hadwiger P, John M, Heil G, Vornlocher HP, Nordheim A.

Blood. 2003 Apr 15;101(8):3157-63. Epub 2002 Dec 12.

17.

Williams-Beuren syndrome critical region-5/non-T-cell activation linker: a novel target gene of AML1/ETO.

Fliegauf M, Stock M, Berg T, Lübbert M.

Oncogene. 2004 Dec 2;23(56):9070-81.

PMID:
15489901
18.

Epigenetic consequences of AML1-ETO action at the human c-FMS locus.

Follows GA, Tagoh H, Lefevre P, Hodge D, Morgan GJ, Bonifer C.

EMBO J. 2003 Jun 2;22(11):2798-809.

19.
20.

The t(8;21) fusion protein, AML1 ETO, specifically represses the transcription of the p14(ARF) tumor suppressor in acute myeloid leukemia.

Linggi B, Müller-Tidow C, van de Locht L, Hu M, Nip J, Serve H, Berdel WE, van der Reijden B, Quelle DE, Rowley JD, Cleveland J, Jansen JH, Pandolfi PP, Hiebert SW.

Nat Med. 2002 Jul;8(7):743-50. Epub 2002 Jun 24.

PMID:
12091906

Supplemental Content

Support Center